treatment

FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer

FDA Oncology shared on X:

“FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer.”

Source: FDA Oncology/X

Adagrasib cancer cetuximab colorectal cancer FDA FDA Oncology Headlines KRAS OncoDaily Oncology